Chronic treatment with oral @entity3034 is associated with an increased frequency of motor complications in the late stages of @entity191 ( @entity191 ). Continuous administration of @entity19432 intestinal gel (LCIG- @entity67097 (  ), Abbott Laboratories), which has been available in Romania since 2009, represents an option for treating @entity1 with advanced @entity191 . Our primary objective was to report changes in motor complications after initiation of LCIG therapy. The secondary objectives were as follows: to determine the impact of LCIG therapy on the daily @entity3034 dose variation before/and after LCIG, to collect @entity1 self-assessments of quality of life (QoL), and to study the overall tolerability and safety of LCIG administration. A retrospective analysis (2009-2013) of LCIG therapy and the experience in nine neurology centers in Romania was performed. The impact of LCIG therapy was evaluated by analyzing changes in motor fluctuations, @entity910 and the @entity1 ' QoL after initiating therapy. The safety of LCIG therapy was estimated by noting agent-related adverse events (AEs) and medical device-related AEs. In the 113 @entity1 included, we observed a significant improvement in @entity191 symptoms after initiation of LCIG therapy. The "on" period increased, with a mean value of 6.14  h, and the @entity910 period was reduced, with a mean value of 29.4  %. The quantified non-motor symptoms subsided. The @entity1 exhibited significant improvements in QoL scores. There were few AEs and few cases of LCIG therapy discontinuation. LCIG is an important and available therapeutic option for managing @entity1 with advanced @entity191 .

The effect of XXXX intestinal gel infusion long-term therapy on motor complications in advanced @entity191 : a multicenter Romanian experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3034 :: ('MESH:D007980', 'Chemical') :: ['levodopa'] @entity19432 :: ('C009265', 'Chemical') :: ['levodopa-carbidopa'] @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD'] @entity67097 :: ('MESH:C009265', 'Chemical') :: ['Duodopa']
@entity19432 :: (C009265,Chemical) :: ['levodopa-carbidopa']
